Previous 10 | Next 10 |
AAON , AAWW , ABC , ABMD , ADM , AGIO , AKRX , ALE , AMCR , ARW , ASIX , AVP , BCE , BCPC , BLD , BLL , BPL , BPMC , BR , BSIG , CBRE , CI , CLVS , CLX , CNHI , CNQ , CNSL , CROX , CRS , CWT , DD , DEA , DLPH , DNKN , EIGI , EXC , GIL , GLOG , GM , GN...
Idea Slides Introduction RET mutations are seen in ~2% of NSCLCs. Currently, there are no FDA-approved treatments for RET-mutated NSCLC. Multi-targeted drugs have been tested in these patients, but without much success. RET-targeted therapies like Blueprint Medicines' ( BPMC ) and L...
CAMBRIDGE, Mass. , July 25, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a....
Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...
Note: This article was first revealed to subscribers to my exclusive marketplace, The Formula , in February when shares of Blueprint were trading < $80. Preface Documents: 10-Q | Company Slides Shares: 48,853,933 | PPS: $100 | Market Cap: $4.8B | Enterprise Value...
Blueprint Medicines (NASDAQ: BPMC ) initiated with Outperform rating and $120 (22% upside) price target at Baird. More news on: Blueprint Medicines Corporation, Millendo Therapeutics, Inc., HealthEquity, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The European Medicines Agency (EMA) accepts for review Blueprint Medicines' (NASDAQ: BPMC ) marketing application seeking approval to use lead candidate avapritinib (BLU-285) to treat adult patients with PDGFRα D842V-mutant gastrointestinal stromal tumors (GIST), regardless of prior...
CAMBRIDGE, Mass. , July 18, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines Agency (EMA) has validated the comp...
Outlook Therapeutics (NASDAQ: OTLK ) initiated with Buy rating and $8 (310% upside) at H.C. Wainwright. Shares up 11% premarket. More news on: Outlook Therapeutics, Inc., Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov...
by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-07-29 07:15:06 ET Barclays analyst issues EQUAL-WEIGHT recommendation for BPMC on July 29, 2024 05:43AM ET. The previous analyst recommendation was Equal-Weight. BPMC was trading at $112.19 at issue of the analyst recommendation. The overall analyst consensus : BUY....
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $105.00 for BPMC on 2024-07-29 05:43:00. The adjusted price target was set to $105.00. At the time of the announcement, BPMC was trading at $112.19. The overall price target consensus is at $100.7...
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...